Holdings
Atle Fund Management AB
As of Jun 30, 2026, Atle Fund Management AB reported 37 positions worth US$352M. Largest: Eli Lilly And Company, Merck & Company, Inc. and Johnson & Johnson. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Eli Lilly And Company | 29,821 | US$35.8M | −9,901 | Jun 30, 2026 |
| Merck & Company, Inc. | 189K | US$24.3M | +156K | Jun 30, 2026 |
| Johnson & Johnson | 85,425 | US$21.7M | −6,952 | Jun 30, 2026 |
| Abbvie Inc. | 64,325 | US$16.2M | −43,856 | Jun 30, 2026 |
| Cvs Health Corporation | 146K | US$15.1M | +122K | Jun 30, 2026 |
| Thermo Fisher Scientific Inc | 27,859 | US$14M | +4,873 | Jun 30, 2026 |
| Revolution Medicines, Inc. | 73,077 | US$13.7M | −544K | Jun 30, 2026 |
| Biogen Inc. | 62,781 | US$13.6M | new | Jun 30, 2026 |
| Neurocrine Biosciences, Inc. | 72,898 | US$12.3M | −16,787 | Jun 30, 2026 |
| Mirum Pharmaceuticals, Inc. | 101K | US$11.8M | −94,961 | Jun 30, 2026 |